Acute administration of tirofiban versus aspirin in emergent carotid artery stenting.


Journal

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
ISSN: 2385-2011
Titre abrégé: Interv Neuroradiol
Pays: United States
ID NLM: 9602695

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 6 11 2018
medline: 6 8 2019
entrez: 6 11 2018
Statut: ppublish

Résumé

Carotid artery stenting requires antiplatelet therapy for prevention of in-stent thrombosis. Patients suffering from acute ischemic stroke undergoing intravenous thrombolysis and emergent carotid artery stenting (eCAS) are at high risk for intracranial bleeding. We assessed efficacy and safety of acute administration of intravenous tirofiban versus aspirin in these patients. A retrospective, single center, cohort study was carried out of 32 patients who underwent eCAS (18 received tirofiban, 14 received aspirin) at our comprehensive stroke center (2008-2016). Of our 32 consecutive eCAS patients, favorable clinical outcomes (modified Rankin scale ≤ 2) were achieved in eight (47%) tirofiban patients and six (46%) aspirin patients ( p = 0.96). Overall rates were similar for symptomatic intracranial bleeding (tirofiban 22%, aspirin 29%, p = 0.68) and mortality (tirofiban 18%, aspirin 23%, p = 0.71). Tirofiban and aspirin demonstrated similar efficacy and safety in thrombolyzed stroke patients who underwent eCAS in our cohort. Intravenous tirofiban with its short half-life might represent an alternative to aspirin in select patients.

Sections du résumé

BACKGROUND BACKGROUND
Carotid artery stenting requires antiplatelet therapy for prevention of in-stent thrombosis. Patients suffering from acute ischemic stroke undergoing intravenous thrombolysis and emergent carotid artery stenting (eCAS) are at high risk for intracranial bleeding. We assessed efficacy and safety of acute administration of intravenous tirofiban versus aspirin in these patients.
METHODS METHODS
A retrospective, single center, cohort study was carried out of 32 patients who underwent eCAS (18 received tirofiban, 14 received aspirin) at our comprehensive stroke center (2008-2016).
RESULTS RESULTS
Of our 32 consecutive eCAS patients, favorable clinical outcomes (modified Rankin scale ≤ 2) were achieved in eight (47%) tirofiban patients and six (46%) aspirin patients ( p = 0.96). Overall rates were similar for symptomatic intracranial bleeding (tirofiban 22%, aspirin 29%, p = 0.68) and mortality (tirofiban 18%, aspirin 23%, p = 0.71).
CONCLUSIONS CONCLUSIONS
Tirofiban and aspirin demonstrated similar efficacy and safety in thrombolyzed stroke patients who underwent eCAS in our cohort. Intravenous tirofiban with its short half-life might represent an alternative to aspirin in select patients.

Identifiants

pubmed: 30394839
doi: 10.1177/1591019918808777
pmc: PMC6448368
doi:

Substances chimiques

Fibrinolytic Agents 0
Tirofiban GGX234SI5H
Aspirin R16CO5Y76E

Types de publication

Journal Article

Langues

eng

Pagination

219-224

Références

Lancet. 2000 May 13;355(9216):1670-4
pubmed: 10905241
Stroke. 2001 Nov;32(11):2559-66
pubmed: 11692017
Stroke. 2003 Aug;34(8):e109-37
pubmed: 12869717
Clin Res Cardiol. 2007 Oct;96(10):730-7
pubmed: 17593309
Stroke. 2008 Jan;39(1):87-99
pubmed: 18032739
N Engl J Med. 2008 Sep 25;359(13):1317-29
pubmed: 18815396
Neurology. 2009 Jun 16;72(24):2104-10
pubmed: 19528517
Stroke. 2009 Sep;40(9):3001-5
pubmed: 19590055
Stroke. 2011 Aug;42(8):e464-540
pubmed: 21282493
Stroke. 2011 Jun;42(6):1653-7
pubmed: 21512175
Stroke. 2011 Sep;42(9):2388-92
pubmed: 21852609
Lancet. 2012 Aug 25;380(9843):731-7
pubmed: 22748820
J Stroke Cerebrovasc Dis. 2013 Nov;22(8):1326-31
pubmed: 23352679
Stroke. 2013 May;44(5):1453-5
pubmed: 23463755
AJNR Am J Neuroradiol. 2014 Apr;35(4):741-6
pubmed: 24157733
J Neurointerv Surg. 2015 Mar;7(3):170-5
pubmed: 25387730
AJNR Am J Neuroradiol. 2015 Dec;36(12):2340-5
pubmed: 26294652
Eur Radiol. 2017 Jan;27(1):247-254
pubmed: 27085698
Stroke. 2016 Oct;47(10):2649-51
pubmed: 27608821
Cerebrovasc Dis. 1998;8 Suppl 5:8-18
pubmed: 9767194
N Engl J Med. 1998 Nov 12;339(20):1415-25
pubmed: 9811916

Auteurs

Philipp Gruber (P)

1 Department of Neuroradiology, Cantonal Hospital Aarau, Aarau, Switzerland.
2 Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.

Martin Hlavica (M)

1 Department of Neuroradiology, Cantonal Hospital Aarau, Aarau, Switzerland.

Jatta Berberat (J)

1 Department of Neuroradiology, Cantonal Hospital Aarau, Aarau, Switzerland.

Benjamin Victor Ineichen (B)

3 Brain Research Institute, University of Zurich, Zurich, Switzerland.
4 Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.

Michael Diepers (M)

1 Department of Neuroradiology, Cantonal Hospital Aarau, Aarau, Switzerland.

Krassen Nedeltchev (K)

2 Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.

Timo Kahles (T)

2 Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.

Luca Remonda (L)

5 Department of Neuroradiology, Cantonal Hospital Aarau, Aarau, University of Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH